Arrowhead Pharmaceuticals, Inc. ARWR
65.92
(0.15)
(0.23%)
as of 25 Sep
- Market cap
- $9.3B
- P/E
- 0.0×
Follow ARWR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(0.47%) | 65.38% | (46.90%) | (64.91%) | |
| (0.13%) | 15.45% | (15.67%) | (18.32%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(0.14%) | 16.78% | (15.68%) | (18.16%) | |
Average Days of Receivables |
3.00 | 73.23 | 9.20 | 4.66 | |
Free Cash Flow per Share |
1.17 | 2.35 | (0.36) | (0.52) | |
Free Cash Flow |
156.89 | 322.01 | (50.87) | (75.11) | |
Capital Expenditures |
(22.67) | (17.30) | (14.57) | (16.06) | |
Piotroski F-Score |
5.00 | 6.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
10.70% | 20.17% | (1.11%) | (2.01%) | |
Accounts Receivable Turnover |
205.54 | 9.86 | 68.92 | 73.35 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.42) | (0.08) | 0.08 | 0.08 | |
Research and Development Expense of Revenue |
73.20% | 59.34% | 110.53% | 108.05% | |
Selling, General and Administrative Expense of Revenue |
14.94% | 13.11% | 25.14% | 25.78% | |
Share Based Compensation of Revenue |
7.64% | 6.19% | 10.96% | 10.46% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(110.09) | 1.68 | 0.12 | 0.18 | |
Depreciation/Fixed assets |
0.05 | 0.05 | 0.05 | 0.06 | |
Capex/Depreciation |
(1.25) | (0.90) | (0.71) | (0.73) | |
Revenue per Share |
6.20 | 7.96 | 4.37 | 4.67 | |
Operating CF per Share |
1.34 | 2.48 | (0.25) | (0.41) | |
Capex per Share |
(0.17) | (0.13) | (0.10) | (0.11) | |
Capex to Sales |
0.03 | 0.02 | 0.02 | 0.02 | |
Net Profit Margin |
(0.20%) | 18.54% | (48.38%) | (47.79%) |
Columns are period end dates